Sarcopenia and targeted therapy in liver cancer
Part of Brain & nervous system, Cancer, Digestive system clinical trials.
This study looks at muscle loss in people with liver cancer who are receiving targeted therapy (TKIs). It aims to understand how muscle health affects treatment outcomes. You may qualify if you have intermediate or advanced liver cancer or earlier stage that hasn't responded to prior treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- 18 years or older
- Diagnosed with hepatocellular carcinoma (a type of liver cancer) by biopsy or imaging
- Liver cancer is at an intermediate, advanced, or early stage that hasn't responded to prior local treatments
- Starting or already on a type of targeted therapy called a TKI
- Had a CT scan within the last 8 weeks before starting TKI therapy
- Agree to participate and sign a consent form
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at how muscle loss (sarcopenia) and overall health affect outcomes in people with B-cell lymphoma who are receiving CAR-T cell therapy. It may help doctors better support patients before and after treatment.
This trial tests a new approach to treat sarcopenia (age-related muscle loss) by targeting a protein called HIF-1α. It compares older adults with sarcopenia to younger adults without it, all of whom are having hip or knee surgery.
This study looks at whether measuring certain proteins in your blood (myokines) can help detect muscle loss (sarcopenia) in people with liver cancer, and compares these blood tests to special CT scans. If you're newly diagnosed with liver cancer and have a CT scan already, you may be able to join.
This study looks at how loss of muscle strength or mass (sarcopenia) relates to advanced liver disease. It may help doctors understand which patients are at higher risk and could guide future care choices.
This trial tests new treatment plans for people with advanced liver cancer that has worsened after initial therapy. The goal is to find more effective, personalized options based on how your cancer responds.
This study is testing whether combining targeted therapy with immunotherapy (or using two immunotherapies together) can help people with liver cancer that cannot be surgically removed. The goal is to understand how well these treatments work and how they affect biomarkers (signals in your body that show treatment response).
Hear when a new HCC - Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.